Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis/Atopic Eczema – China In-Depth (China )
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with conventional topical and/or systemic agents. Topicals are usually effective for mild cases but not for moderate to severe disease; topicals may also have suboptimal safety, tolerability, and compliance. Thus, there is significant unmet need for more-efficacious therapies for topical-refractory patients and for those with moderate to severe AD. China’s National Medical Products Administration (NMPA) has approved the targeted therapies Dupixent (Sanofi’s dupilumab), Rinvoq (AbbVie’s upadacitinib), and Cibinqo (Pfizer’s abrocitinib) for moderate to severe AD, and many other targeted therapies are in the pipeline. This report provides a comprehensive analysis of China’s AD patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
Questions answered
- How large is China’s drug-treatable AD population, and how will the drug-treatment rate change over the forecast period?
- Which drugs are the most commercially relevant in China’s AD market and why?
- What are interviewed experts’ insights into current treatments?
- What are the key unmet needs in the management of AD in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for AD in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content highlights
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists and pediatricians.
Epidemiology: Diagnosed prevalence of AD in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient shares of key AD therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 7 agents; Phase II: 10 agents; coverage of select early-phase products.
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
